Sangamo Therapeutics Inc (NASDAQ:SGMO) has a beta value of 1.47 and has seen 0.97 million shares traded in the recent trading session. The company, currently valued at $247.25M, closed the recent trade at $1.18 per share which meant it gained $0.01 on the day or 1.28% during that session. The SGMO stock price is -169.49% off its 52-week high price of $3.18 and 74.58% above the 52-week low of $0.30. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.82 million shares traded. The 3-month trading volume is 6.77 million shares.
The consensus among analysts is that Sangamo Therapeutics Inc (SGMO) is Hold stock at the moment, with a recommendation rating of 1.88. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 3 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Sporting 1.28% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the SGMO stock price touched $1.18 or saw a rise of 4.71%. Year-to-date, Sangamo Therapeutics Inc shares have moved 16.18%, while the 5-day performance has seen it change 2.16%. Over the past 30 days, the shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) have changed 7.73%. Short interest in the company has seen 24.33 million shares shorted with days to cover at 3.14.
Wall Street analysts have a consensus price target for the stock at $2.5, which means that the shares’ value could jump 52.8% from the levels at last check today. The projected low price target is $2.0 while the price target rests at a high of $3.0. In that case, then, we find that the latest price level in today’s session is -154.24% off the targeted high while a plunge would see the stock gain -69.49% from the levels at last check today.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
The company’s shares have gained 33.15% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -15.96% over the past 5 years. Earnings growth for 2025 is a modest 68.41% while over the next 5 years, the company’s earnings are expected to increase by 43.70%.
SGMO Dividends
Sangamo Therapeutics Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
Insiders own 2.38% of the company shares, while shares held by institutions stand at 29.58% with a share float percentage of 30.30%. Investors are also buoyed by the number of investors in a company, with Sangamo Therapeutics Inc having a total of 150.0 institutions that hold shares in the company. The top two institutional holders are WASATCH ADVISORS LP with over 20.09 million shares worth more than $7.2 million. As of 2024-06-30, WASATCH ADVISORS LP held 11.1403% of shares outstanding.
The other major institutional holder is ARMISTICE CAPITAL, LLC, with the holding of over 14.06 million shares as of 2024-06-30. The firm’s total holdings are worth over $5.04 million and represent 7.7963% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Wasatch Ultra Growth Fund and Wasatch Microcap Fund. As of Sep 30, 2024, the former fund manager holds about 5.26% shares in the company for having 10.97 shares of worth $12.78 million while later fund manager owns 5.65 shares of worth $6.58 million as of Sep 30, 2024, which makes it owner of about 2.71% of company’s outstanding stock.
